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Abstract
Insulin is an effective treatment for achieving tight glycemic control and improving clinical outcomes
in patients with diabetes. While insulin therapy is required from the onset of diagnosis in type 1
disease, its role in type 2 diabetes requires consideration as to when to initiate and advance
therapy. In this article, we review a case study that unfolds over 5 years and discuss the therapeutic
decision points, initiation and advancement of insulin regimens, and analyze new data regarding the
advantages and disadvantages of tight management of glucose levels.
Introduction
Diabetes currently affects 23.6 million people in the
United States [1,2] and 246 million people worldwide,
and it is expected to increase to 380 million by 2025 [3].
In the United States, type 2 diabetes (T2D) accounts for
90% of all newly diagnosed cases. There are 57 million
Americans who have prediabetes and 5%–7% of these
people progress to T2D each year [1]. People with T2D
have an increased risk for vascular complications, most of
which can be prevented with aggressive management of
the metabolic disturbances that are associated with the
disease.
Data from the National Health and Nutrition Examina-
tion Survey (NHANES) demonstrate that the proportion
of adults in the U.S. with diagnosed and adequately con-
trolled T2D increased significantly between 1999–2000
and 2003–2004. Overall, only 37% of the adults in
NHANES 1999–2000 had HbA1C (A1C) levels at the
American Diabetes Association (ADA) goal of < 7% and
only 36% had a blood pressure of 130/80 mm/Hg, and
just 50% had a total cholesterol < 200 mg/dL, while in the
2003–2004 study 56.8% of patients reached a goal A1C of
<7% [4,5]. Thus, only half of the people with T2D are ade-
quately managed for glucose control and overall only 7%
are at goal for blood pressure, lipids and glucose [4].
Implementing clinical guidelines from the American Dia-
betes Association [6], the American Association of Clini-
cal Endocrinologists [7] and understanding the newer
consensus statement from the American Diabetes Associ-
ation and the European Association for the Study of Dia-
betes [8] and recommendations from the Texas Diabetes
Council [9] could help explain the decrease in A1C levels
in recent years.
The following case presentation will exemplify chronolog-
ically the onset of T2D and therapeutic decisions that are
involved in prevention and delay strategies, use of oral
agents, incretin-based therapies, and transition to insulin
management.
Case presentation
Ruth was a young woman, age 26 years, when she was first seen
as a new patient in the clinic. She worked at a nightclub and
had earned some college credits toward a degree in elementary
education. Although she had no known health problems, she
had questions and concerns about her risks for diabetes and
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wanted some screening tests performed. Both of her parents had
T2D and developed renal complications. At the visit, Ruth
weighed 134 lbs and was 5'4" tall (BMI = 23 kg/m2). Baseline
screening studies revealed her fasting glucose to be 86 mg/dL
and liver function to be normal. Lipids showed triglycerides 213
mg/dL, high-density lipoprotein cholesterol (HDL-C) 38 mg/
dL, and low-density lipoprotein cholesterol (LDL-C) 136 mg/
dL.
Question 1: What would you tell Ruth about her risk of
developing T2D and can it be prevented?
Answer: Impaired glucose metabolism is common in first-
degree relatives of patients with T2D. Offspring of these
patients have a 30%–40% chance of developing T2D [10]
and frequently demonstrate abnormal glucose tolerance
and several associated metabolic abnormalities such as
low insulin release or insulin resistance [11-13].
Thus, although her glucose is currently in the normal
range, keeping in mind her family history, Ruth probably
would have a tendency to develop insulin resistance. The
best strategy at this point is to recommend lifestyle
changes that include nutrition therapy and regular physi-
cal activity. Because of the effects of obesity on insulin
resistance, weight loss is an important therapeutic objec-
tive in overweight or obese individuals [14]. Simple atten-
tion to lifestyle has been demonstrated to be superior to
medications for the prevention and delay of T2D in sev-
eral studies [15-19]. Furthermore, this approach will have
a positive impact on the lipid abnormalities [20].
Short-term studies have shown that moderate weight loss
(~5% of body weight) in T2D patients is associated with
decreased insulin resistance, improved glycemic control,
and improved measures of lipemia and blood pressure
[15]. Intensive lifestyle intervention employed in the dia-
betes prevention program (DPP) and maintenance of
weight loss at ~5% over 3 years led to a 58% reduction in
the incidence of T2D [16]. One-year results from the look
AHEAD (Action for Health in Diabetes) study demon-
strated that intense lifestyle intervention resulted in an
average of 8.6% weight loss, reduction of A1C, and reduc-
tion of several cardiovascular disease risk factors [21].
Since Ruth's BMI (23 kg/m2) is currently normal, based on
the ADA guidelines [6], it was recommended that she per-
form at least 150 minutes/week of moderate-intensity aer-
obic physical activity. Resistance training three times per
week is an alternative.
Subsequently, Ruth disappeared from the clinic for 3 years.
When she returned, life had taken some different turns. Two
years ago she had become pregnant and developed gestational
diabetes. Diet and exercise were successful for managing the
glucose abnormality and her baby did well. However, physical
examination now showed that her weight was 174 lbs (BMI =
29.9 kg/m2) and a random blood sugar was 208 mg/dL.
Question 2. Do you think Ruth now has T2D?
Answer: Ruth may have T2D, but the formal diagnosis is
based on observing an abnormal glucose and then con-
firming the glucose abnormality. That is, two tests are
needed to make the diagnosis. The gold standard for diag-
nosing T2D is still the oral glucose tolerance test. It is
more sensitive than the simplified methods of measuring
fasting glucose on two occasions or finding a random glu-
cose ≥200 mg/dL in a symptomatic person [6].
There is good reason to recommend that Ruth have a glu-
cose challenge: First, we already know that she is geneti-
cally predisposed to develop T2D, and she has gained 40
pounds. Second is the fact that she developed gestational
diabetes: Ruth has failed the endocrinologist's "stress test"
in that she was unable to handle the increased metabolic
demands of pregnancy 2 years ago, and gestational diabe-
tes is a very high risk factor for subsequent T2D. Overall,
almost 50% of Caucasian and up to 80% of Hispanic
women who have had gestational diabetes will progress to
T2D within 5 years [22-25].
Ruth was shocked when told she might have diabetes and that
confirmatory tests were needed. However, she declined further
testing at this time and said she was going to get serious about
losing weight and then do the tests. Three months later when
she returned her weight was still 172 lbs.
Question 3: If a subsequent oral glucose tolerance test is
positive for T2D, does Ruth need further evaluations to
differentiate type 1 diabetes from T2D?
Answer: Based on Ruth's history of gestational diabetes,
weight gain, her family history of diabetes, and the rate of
onset of hyperglycemia it is very likely that she has T2D.
Specialized tests are not indicated for this patient. Testing
for insulin C-peptide, anti-islet cell (ICA), and anti-insu-
lin (IAA), or antiglutamic acid decarboxylase (GAD) anti-
bodies is a matter of clinical judgment. These studies may
be considered in non-obese adults who present with a T2D-
like picture and for whom it is unclear whether the patient
is catabolic [26]. An estimated 20% of such patients
thought to have T2D actually have latent autoimmune
diabetes or type 1 diabetes. These patients will require (or
soon will require) an insulin-based therapeutic regimen.
Although the antibody panel helps to differentiate T2D
from latent autoimmune diabetes, it must be emphasized
that these tests are not diagnostic for the latter. However,
the picture is different in pediatric cases of diabetes. Pedi-
atric endocrinologists often obtain autoantibody markersOsteopathic Medicine and Primary Care 2009, 3:5 http://www.om-pc.com/content/3/1/5
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and C-peptide levels in children presenting with hypergly-
cemia [27].
Ruth proceeded to have an oral glucose tolerance test and the
diagnosis of T2D was confirmed. Further baseline studies
revealed normal renal and hepatic function, the urine micro-
albumin to creatinine ratio was 6 mcg/mg (normal <20), and
the A1C was 6.6%. She had already started maintaining self-
monitored blood glucose (SMBG) records. A review showed the
fasting glucose to average 120 mg/dL and the 2-hour postpran-
dial values averaged 180 mg/dL. Ruth knew what the values in
the SMBG records meant and was overwhelmed at the prospect
of lifelong treatment of diabetes.
Question 4: What therapy options would you recom-
mend to Ruth?
Answer: Diet, exercise, and weight control always remain
the cornerstones of any therapeutic plan in T2D. In addi-
tion, Ruth needs to begin monotherapy with an oral anti-
diabetic drug. Monotherapy is appropriate in a clinical
setting where A1C levels are ≤7% with no evidence of
micro- or macrovascular complications. At this stage, any
oral antidiabetic medication (thiazolidinediones, dipepti-
dyl peptidase-4 inhibitors, alpha glucosidase inhibitors,
biguinides, glinides or sulfonylureas) can be considered
appropriate. However, metformin is generally recom-
mended as the initial pharmacological agent in those with
normal renal function [8]. Also, insulin is always an
option for initial therapy [8,9].
Some physicians believe that patients gain much weight if
prescribed a thiazolidinedione (TZD) rather than an alter-
native therapy. However, data reveal this is not true.
Depending on the source, weight gains of about 1 to 3.6
kg are seen with TZD-managed patients who follow a diet
and exercise plan [28,29]. Large weight gain occurs when
patients begin using a TZD and do not change their eating
habits. Some patients (5%) taking a TZD will develop
edema and it is well appreciated that TZDs should be
avoided in patients with decreased ventricular function
(New York Heart Association class 3 or 4 failure) [30].
Although the FDA still recommends analysis of liver
enzymes every 3 months for the first year of TZD therapy
[31], it should be noted that the newer TZDs, rosiglita-
zone and pioglitazone, have not been associated with
transaminitis.
Numerous studies have shown that some sulfonylureas
are associated with higher risk of hypoglycemia [32-34].
However, glipizide and glimepiride are considered safer
because they are associated with less hypoglycemia [35].
Ruth began using metformin and the dose was titrated upward.
However, after 3 months, glycemic control remained subopti-
mal. The fasting glucose averaged 145 mg/dL and her mean 2
hr postprandial levels were 220 mg/dL. The A1C study was
updated and found to be 7.1%.
Question 5: What would be your next recommendation
to Ruth for achieving glycemic control?
Answer: Ruth needs combination therapy. Two-drug regi-
mens are indicated in persons with an A1C of 6.5% to
<8% if they are already on monotherapy. Incidentally,
combination therapy is indicated as initial therapy for
treatment-naïve patients with an A1C of 7% to 8% [7].
Combination therapy may include any two oral agents, as
long as each drug is from a different class. It would make
no sense to place a patient on two sulfonylureas or two
TZDs. One might also consider adding an incretin
mimetic such as exenatide or liraglutide to the mono-
therapy program if the A1C was ≤1% above goal. Again,
insulin is an option at any A1C level [7].
Ruth opted to combine sitagliptin, a DPP-4 inhibitor, with the
metformin as the next step to control her diabetes. Her glycemic
control improved markedly and she was very pleased that the
A1C remained around 6.5%. However, laboratory studies a
year later demonstrated progression of her diabetes. The A1C
had increased to 7.8%. Her BUN, creatinine, and hepatic
functions remained normal, but the urine microalbumin to cre-
atinine ratio was now abnormal at 30 mcg/mg. Her SMBG
records were roughly consistent with the A1C; the fasting aver-
age was approximately 155 mg/dL and the daytime glucose
averaged 170 mg/dL. Combination therapy with two oral
agents was no longer effective.
Question 6: What is the next step? Should you add a third
pill? Add an incretin mimetic? Start insulin?
Answer: Clinical judgment must come into play and be
weighed with the patient's wishes on escalating therapy.
The A1C is 7.8% and this places us on the cusp for several
appropriate clinical decisions. Some physicians might add
a third oral agent, some might recommend exenatide, and
still others would initiate insulin. The rationale for select-
ing the next therapy can be simplified by using the follow-
ing maxim: In general, each oral agent alone can reduce
the A1C by 1.0%–2.0%, but each added oral agent results
in further A1C reductions of about 1% [36]. Exenatide
will usually reduce the A1C about 1% [37]. Thus, adding
an additional pill or incretin mimetic to an existing regi-
men may be effective if the A1C is ≤1% above goal. If the
A1C is >1% above goal, then adding a third agent may not
be an effective strategy. Such patients would probably
need insulin. If insulin is selected as the next step, many
physicians stop or decrease the sulfonylurea. At this time,
exenatide and sitagliptin are not approved for use with
insulin. If the patient is taking metformin and/or a TZD,
most physicians would continue these because they are, in
effect, "insulin sensitizers."Osteopathic Medicine and Primary Care 2009, 3:5 http://www.om-pc.com/content/3/1/5
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In the current case study, when Ruth's glucose control
slipped, and A1C levels increased to 7.8%, we notice the
incidence of microalbuminuria, which is a major risk fac-
tor for renal and cardiovascular events. The Heart Out-
comes Prevention and Evaluation Study demonstrated
that microalbuminuria increased the relative risk for
major cardiovascular events by 1.83-fold and hospitaliza-
tion for heart failure by 3.23-fold [38]. There is a wealth
of data that show significant risk reductions for incident
microalbuminuria in individuals treated to achieve tight
glycemic control. Data from the BENEDICT trial [39]
demonstrated that the risk of developing microalbuminu-
ria can be effectively reduced.
Although reluctant to begin insulin, Ruth came to the conclu-
sion that an insulin regimen was probably the best approach.
She considered the rate at which her diabetes had progressed
and the value of achieving tight control. She remembered her
parents and their downhill course with kidney failure. She also
remembered what she learned about tight glucose control and
the remarkable reductions in microvascular disease. So,
although a third oral agent and exenatide were viable options,
she decided to start insulin. She was most excited to discover
that insulin injections were almost "trivial" with the pen sys-
tems and micro needles and eliminated the inconvenience of
carrying insulin vials and syringes. There is also data demon-
strating that using pen devices may result in better glycemic
control [40,41].
At the first return visit to review glycemic control and titrate the
insulin dose, Ruth reported that "If I shoot a stretch mark, I
absolutely can't feel anything!" She was reminded that insulin
absorption was altered in scar tissue and that she should use a
different site on the abdomen. She declined to change and said
that she had now grown to love her "ugly stripes."
Question 7: How is insulin therapy initiated?
Answer: The goal of insulin administration in patients
with diabetes is to mimic normal physiologic secretion of
insulin to control both fasting plasma glucose (FPG) and
postprandial glucose (PPG) levels. There are several ways
to start insulin as long as the dose and timing are appro-
priate. The challenge is to actually start insulin when it's
indicated and not delay therapy until end-organ problems
surface. Insulin should be started within 3–6 months if
combination therapy cannot achieve A1C goals [20].
Historically, regular human insulin (RHI) was used to
control PPG and the intermediate-acting neutral pro-
tamine Hagedorn (NPH) was used to control basal glu-
cose. These remain effective insulin preparations, but the
newer insulin analogs are replacing RHI and NPH. Both
RHI and NPH exhibit considerable intra- and interpatient
variability in absorption [42-44]. Aspart, glulisine or lis-
pro are preferred by many patients over RHI because life-
style flexibility is afforded due to their rapid absorptions
and short duration of action [44]. For example, in contrast
to RHI, which must be administered at least 30 minutes
before a meal and has an effective duration of 4 hours,
rapid-acting insulin analogs can be administered within
15 minutes before eating, at the start of a meal or even
after a meal and its effects wane within 2 hours [45]. The
main reason detemir and glargine are used over NPH is
because the risk of hypoglycemia, in particular nocturnal
hypoglycemia, is decreased [46,47].
A patient may start by using 10 units of insulin or 0.10 to
0.25 units insulin per kg on a once-daily regimen [48].
These starting doses are appropriate for glargine, detemir,
NPH, premixed 70/30 aspart-protamine/aspart or 75/25
lispro-protamine/lispro. Glargine or detemir should be
started with a once-daily injection. NPH is often started
with a bedtime injection. Premixed insulin may be started
pre-breakfast and/or pre-dinner [49,50]. As noted above,
the oral agents are continued except for adjustments if a
sulfonylurea had been used. Exenatide should be discon-
tinued because study results are not yet available on its use
with insulin.
The old rule for starting insulin was simple and the goal
was to control the fasting glucose first because that set the
tone for the entire day. The insulin dose was increased
every 2–3 days in 2- to 3-unit increments until the fasting
glucose is controlled [48,51]. The second goal was then to
control the daytime glucose. The old rule works fine if the
patient is still deriving benefit from the oral agents. Spe-
cifically, once-daily insulin is sufficient if control is
achieved  and  the fasting glucose is approximately the
same as the bedtime glucose. Why? We will return to this
point and explain it in our discussion of question 9,
below.
Ruth started using 10 units basal insulin every morning and
titrated the dose herself for 2 weeks. At the return visit, she was
using 18 units and was unhappy because "my sugars are still
crappy." Her SMBG records showed the fasting glucose to aver-
age 124 mg/dL, but they were elevated to 160 mg/dL before
meals and 230 mg/dL 2 hours postprandially. Her first ques-
tions concerned whether she was on the right insulin.
Question 8: What are Ruth's options for glucose manage-
ment?
Answer: Ruth requires either multidose or intensive insu-
lin therapy [36]. The fasting glucose had improved, but
the daytime glycemic excursions were not controlled with
oral agents and basal insulin alone. One option is to
advance directly to intensive therapy with basal glargine
or detemir each morning and prandial aspart, glulisine, orOsteopathic Medicine and Primary Care 2009, 3:5 http://www.om-pc.com/content/3/1/5
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lispro with meals. A second option is switching to
premixed insulin. Again, selection of insulin regimens
needs to be done with considerations of the patient's life
schedules. Basal-prandial schedules involve more injec-
tions, but there is more freedom. That is, the prandial
insulin is used only when and if the patient eats. Premixed
insulin, which contains intermediate and fast-acting insu-
lin, can be used twice or three times daily and requires
fewer injections. However, the patient must adhere to a
daily dietary and activity schedule.
Ruth opted to switch to a twice-daily premixed insulin regimen.
She wanted to give this approach "a few months to see how well
it works." She again stressed that her goal was to control the
sugars. After 6 months, her A1C was 6.4% but she had diffi-
culties adjusting her schedule on weekends and eating on time.
She was happy with her results, but was also eager to try basal-
prandial therapy to determine if it would better fit her lifestyle.
Question 9: How are insulin regimens changed?
Answer: Ruth had achieved good control using premixed
insulin. She had started twice-daily premix based on her
previous dose of basal insulin. She simply divided the old
dose into two injections, 10 units morning and 10 units
in the evening, and titrated up to 25 units each AM and 15
units each PM to achieve control [52]. Now, the question
arises as to the best approach for converting from a twice-
daily premixed regimen to a basal-prandial regimen. Only
one method will be presented here [53]. It should be real-
ized that the following strategy will work for any question
on conversion from a multidose schedule to a basal-pran-
dial regimen. It doesn't matter if the conversion is from
premixed insulin or from NPH plus regular, aspart, gluli-
sine or lispro insulin.
Do this: Simply stop the current therapy and start over
with basal and prandial insulin. The basal insulin should
be glargine or detemir. The prandial insulin should be
aspart, glulisine, or lispro. Because the patient has been on
insulin the weight-based dose is now 0.5 units per kg [52].
(Remember, the patient who was insulin-naïve starts at
0.10 to 0.25 units per kg insulin.) Half of the insulin dose
is given once daily as basal insulin and the other half is
given as aspart, glulisine, or lispro divided among the
three meals. If Ruth weighs 170 pounds (or 77 kg), about
38 units will be needed per day. Thus, she will take 19
units of daily basal insulin and about 6 units of prandial
insulin before each meal. Basal insulin is titrated, as
before, by increasing the dose 2–3 units every 2–3 days
until control of the fasting glucose is attained. The pran-
dial insulin is titrated in a similar fashion: Each dose is
individually adjusted by increasing 1–2 units every 2–3
days until each postprandial value is <140 mg/dL (AACE)
or <180 mg/dL (ADA) [54]. An important point to stress
at this time concerns the ratio of basal to bolus insulin.
The guiding principle is that the basal-prandial regimen
should approximate physiologic insulin delivery. This
means that approximately 50% of the body's insulin
requirements are for management of basal metabolism.
Approximately 50% of the body's insulin requirements
are for disposal of nutrients. The 50:50 ratio is not an iron-
clad rule, but serves as a good starting point for insulin
titrations. Some persons may require 60% basal and 40%
prandial. During pregnancy, 40% basal and 60% prandial
use is not uncommon. At this point, we are going to
explain my statement in Question 7 about why the fasting
and bedtime glucose values should be approximately
equal and give you an important tip on titrating insulin:
Aim for the fasting blood glucose to be about the same as
the blood glucose measured at bedtime! Basal insulin is
used to control hepatic glucose production. It's not
intended to shut-off hepatic glucose production. Basal
insulin is not intended to compensate for an insufficient
dose of prandial insulin. If the patient's bedtime blood
sugar was 220 mg/dL and the fasting glucose is 95 mg/dL,
you are using too much basal insulin and not enough sup-
per time prandial insulin. It's also a good bet that the
patient with high bedtime sugars and "well-controlled"
AM sugars probably had an unrecognized hypoglycemic
event at sometime during the night.
Question 10: What if Ruth had opted to stay on basal
insulin, not start premix, and needed to add prandial cov-
erage?
Answer: Ruth was approaching the fasting glucose goal
but the daytime sugars were high. To address this, aspart,
glulisine or lispro would have been added to each uncon-
trolled meal time. The starting dose of prandial insulin is
5 units or 0.1 units/kg and each dose of prandial insulin
is titrated as above to achieve the 2-hour postprandial
goals. Here is the tip we teach residents: When adding
prandial insulin to an ongoing basal regimen, decrease
the basal dose about 10% for each added prandial dose.
Then, don't forget that during this titration period, you
want the bedtime and fasting glucose to be the same.
Once achieved, you can then begin fine tuning the regi-
men.
Over the next year, Ruth did well. Her A1C remained between
6.5 and 7%, the urine microalbumin to creatinine ratio
decreased to 8 mcg/mg, and other markers for renal and hepatic
function remained normal. On a recent follow-up visit to
review glycemic control she had questions about the safety of
insulin therapy. "I heard on the news and everywhere else that
insulin caused low sugars and death. Should I really be taking
it?" Ruth was referring to the headlines on the ACCORD Trial
[55]. This is a common scenario.Osteopathic Medicine and Primary Care 2009, 3:5 http://www.om-pc.com/content/3/1/5
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Question 11: How can we answer Ruth's question about
whether she should continue on insulin therapy?
Answer: Let's start by asking why the NIH-sponsored
ACCORD Trial was done? The rationale was that the
major world studies, including the UK Prospective Diabe-
tes Study [56] did not conclusively demonstrate that tight
glucose control in T2D would reduce the incidence of car-
diovascular disease. Thus, ACCORD was designed to
determine if glucose management in the setting of con-
trolled blood pressure and lipids would reduce macrovas-
cular events. Approximately 10,000 people were recruited,
and it is important to know their characteristics. The par-
ticipants had an average age of 62 years, had long-stand-
ing type 2 diabetes, about 1/3 had a known previous
cardiovascular event and 2/3 had multiple risk factors.
Standard treatment targeted an A1C of 7%–7.9% and
maintained an average of 7.5%. Intensive treatment tar-
geted an A1C of <6% and maintained an average of 6.4%.
The intervention was insulin therapy added to any diabe-
tes control regimen with oral agents or exenatide. So what
was found after 3.5 years? The intensive therapy arm of
the trial was halted 18 months early. The review cited
increased death in the intensive treatment group, possibly
related to hypoglycemia. What made the headlines? Inten-
sive insulin therapy for diabetes causes death.
However, the ACCORD data can be looked at in several
ways. The data did not demonstrate that glycemic control
reduced macrovascular disease but the question is still
considered unanswered by many. Was the increment
change in A1C between intensive and standard therapy
large enough to detect changes in macrovascular out-
comes? Would the impact of glycemic control surface if
the study continued for a longer time? What if emphasis
on glycemic control had been implemented earlier in the
disease course?
From another vantage point, the ACCORD data show very
positive results after controlling blood pressure, lipids and
glucose. Let us use the information from Hafner's study of
mortality from coronary heart disease in diabetic and
nondiabetic subjects with and without a prior history of
myocardial infarction, and whose blood pressure, lipids
and glucose were not controlled [57]. Sixty-two percent of
the participants had hypertension; the average blood glu-
cose was approximately 200 mg/dL and the average LDL
cholesterol was170 mg/dL. Looking at Figure one in Haf-
ner's report, at approximately 3.5 years into the study the
death rate was about 3% per year in those with diabetes
(with or without a prior history of myocardial infarction.)
Now we see the value of treating hyperglycemia, hyperlip-
idemia and hypertension. The observed death rates in the
ACCORD were 1.1% with standard therapy and 1.4% in
the intensive therapy group. If we express the data in terms
of death per thousand patients per year, cardiovascular
death in untreated diabetes is 30/1000 versus 11/1000 and
14/1000 in the ACCORD standard and intensive insulin
therapy groups, respectively. Both standard and intensive
insulin therapy groups showed benefit! It's true that the
death rate between intensive and standard therapy was
statistically significant (3/1000 patient-years) and hence
the intensive intervention was appropriately stopped, but
here are the clinical implications. First, controlling glu-
cose, blood pressure and lipids is effective in preventing
cardiovascular death in patients with diabetes, although
the contribution of glycemic control is unresolved. Sec-
ondly, an A1C of 7.5% appears to be acceptable for older
patients with long-standing diabetes and multiple cardio-
vascular risk factors or disease.
Further support for glucose management in the setting of
controlled blood pressure and lipids comes from the
ADVANCE study [58] which was published in the same
journal with the ACCORD. Similar reductions of major
CV events and overall mortality were reported with inten-
sive and standard insulin therapy. However, unlike the
ACCORD results, no excess death was found with inten-
sive insulin management.
To answer Ruth's question, one can review the following
points. She is 31 years old and not in the 60+ year old cat-
egory. Her A1C is about 6.5% without adverse events or
hypoglycemic episodes. Her urine microalbumin to creat-
inine ratio has improved and insulin was needed to
achieve this degree of control when oral agents had failed.
There are 3 significant take-home messages:
1. Insulin therapy, whether a once-daily regimen with
basal insulin or premixed insulin, is appropriate as an
initial therapy for type 2 diabetes.
2. Insulin therapy should be started when the A1C is
approximately 1% above goal in patients on combina-
tion therapy and must be advanced to a multidose or
basal-prandial regimen if fasting and/or daytime glu-
cose is not at goal.
3. Insulin therapy is beneficial, not deleterious, in the
management of diabetes.
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